Table 1.
Clinical and pathological baseline patient characteristics.
| LRH (n = 36) | ARH (n = 36) | p value | |
|---|---|---|---|
| Age mean | 44.6 | 41.2 | 0.2 |
| Range (SD) | 24–79 (12.2) | 24–73 (12.7) | |
| BMI mean | 25.8 | 26.4 | 0.5 |
| Range (SD) | 19.6–35.8 (3.8) | 19.5–34.7 (4.7) | |
| ASA grade n (%) | 0.06 | ||
| 1 | 26 (72%) | 18 (50%) | |
| ≥2 | 10 (28%) | 18 (50%) | |
| FIGO stage n (%) | 0.2 | ||
| IA2 | 1 (2.7%) | 0 | |
| IB1 | 33 (91.8%) | 36 (100%) | |
| IIA1∗ | 2 (5.5%) | 0 | |
| Histology n (%) | 0.3 | ||
| Squamous cell | 25 (69%) | 20 (55%) | |
| Adenocarcinoma | 11 (31%) | 16 (45%) | |
| Grade n (%) | 0.3 | ||
| 1 | 5 (13.8%) | 12 (33.3%) | |
| 2 | 16 (44.4%) | 15 (41.6%) | |
| 3 | 3 (8.5%) | 3 (8.5%) | |
| n/a | 12 (33.3) | 6 (16.6%) | |
| Tumor max dimension | 0.6 | ||
| Median | 19.5 mm | 16 mm | |
| Range (IQ) | 7–37 (30) | 9–35 (12) | |
| Nodal metastasis n (%) | 4 (11%) | 2 (5.5%) | 0.3 |
| Previous minor abdominal surgery n (%) | 7 (19.4%) | 13 (26%) | 0.1 |
| Follow-up duration (months) | 36 | 36 | 1 |
∗These patients were preoperatively staged as IB1.